Saama, a provider of AI-based solutions to accelerate clinical development and commercialisation, announced on Monday an expanded, multi-year agreement with biopharmaceutical company Pfizer Inc (NYSE:PFE) aimed at accelerating clinical research processes.
Originating from their 2020 collaboration, the expanded partnership builds upon the success of Smart Data Quality (SDQ), an AI-driven solution that notably reduced Pfizer's data review timelines.
Under the new agreement, Pfizer will further implement SDQ to enhance data review processes across its global study portfolio.
Beyond SDQ, the partnership also includes the adoption of Saama's advanced Biometrics Research and Analysis Information Network. This innovative platform is poised to streamline statistical programming and biostatistics workflows, digitise study specifications and produce submission-ready tables, listings and figures (TLF) artifacts. By leveraging these AI-driven solutions, Pfizer anticipates a reduction in regulatory submission timelines, thereby accelerating the approval process for its diverse portfolio of global studies while fostering ongoing automation and innovation.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member